ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Up 31.5% in September

ABIVAX Société Anonyme (NASDAQ:ABVX) saw a large growth in short interest in September. As of September 30th, there was short interest totalling 272,200 shares, a growth of 31.5% from the September 15th total of 207,000 shares. Based on an average trading volume of 91,800 shares, the short-interest ratio is currently 3.0 days. Approximately 0.5% of the company’s stock are sold short.

ABIVAX Société Anonyme Stock Performance

NASDAQ:ABVX opened at $9.54 on Tuesday. The firm has a 50-day moving average price of $11.23 and a two-hundred day moving average price of $12.91. ABIVAX Société Anonyme has a twelve month low of $7.99 and a twelve month high of $17.02.

Wall Street Analysts Forecast Growth

Separately, Laidlaw started coverage on shares of ABIVAX Société Anonyme in a report on Monday, July 29th. They issued a “buy” rating and a $48.00 target price for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $36.50.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new position in ABIVAX Société Anonyme during the 1st quarter valued at about $81,000. Capstone Investment Advisors LLC boosted its stake in shares of ABIVAX Société Anonyme by 9.0% during the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock worth $900,000 after purchasing an additional 5,199 shares during the last quarter. Kennedy Capital Management LLC boosted its stake in shares of ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after purchasing an additional 31,331 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of ABIVAX Société Anonyme by 18.2% during the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after purchasing an additional 131,414 shares during the last quarter. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.